文献速递冠心病

依维莫司洗脱支架与裸金属支架在STEMI患者中的10年随访结果

10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

EXAMINATION试验的10年随访(EXAMINATION-EXTEND)纳入1498例STEMI患者,随机1:1接受依维莫司洗脱支架(EES,n=751)或裸金属支架(BMS,n=747)。主要终点患者导向复合终点(全因死亡、任何心肌梗死或任何血运重建)在EES组显著降低(32.4% vs 38.0%,HR 0.81,95%CI 0.68-0.96,p=0.013),器械导向复合终点亦降低(13.6% vs 18.4%,HR 0.72,95%CI 0.55-0.93,p=0.012),主要由靶病变血运重建驱动(5.7% vs 8.8%,p=0.018)。

要点

  • STEMI患者接受EES较BMS在10年时显著降低患者导向和器械导向复合终点。
  • 获益主要来自靶病变血运重建减少,支架血栓率两组相似。
  • 5至10年间两组器械失败相关不良事件发生率均低。

核心结论

  • 在需要直接PCI的STEMI患者中,EES较BMS在10年随访时确认在患者导向和器械导向复合终点方面具有优势。

研究设计与样本

  • EXAMINATION-EXTEND研究为研究者驱动的EXAMINATION试验10年随访,随机1:1分配1498例STEMI患者至EES组(n=751)或BMS组(n=747)。

主要发现

  • 患者导向复合终点EES组32.4% vs BMS组38.0%(HR 0.81,95%CI 0.68-0.96,p=0.013)。
  • 器械导向复合终点EES组13.6% vs BMS组18.4%(HR 0.72,95%CI 0.55-0.93,p=0.012)。
  • 靶病变血运重建EES组5.7% vs BMS组8.8%(p=0.018)。
  • 确定性支架血栓EES组2.2% vs BMS组2.5%(p=0.590)。
  • 5至10年间靶病变血运重建(1.4% vs 1.3%,p=0.963)和确定性或可能支架血栓(0.6% vs 0.4%,p=0.703)两组无差异。

临床怎么用

  • 对于STEMI行直接PCI的患者,选择EES而非BMS可降低长期复合终点事件风险。

局限性

  • 10年临床随访完整率EES组94.5%、BMS组95.9%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes data for a durable-polymer everolimus-eluting stent (EES) at extended long-term follow-up in patients with ST-segment elevation myocardial infarction (STEMI) are unknown. OBJECTIVES: The aim of this study was to assess the 10-year outcomes of patients enrolled in the EXAMINATION (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction) trial. METHODS: The EXAMINATION-EXTEND (10-Years Follow-Up of the EXAMINATION Trial) study is an investigator-driven 10-year follow-up of the EXAMINATION trial, which randomly assigned 1,498 patients with STEMI in a 1:1 ratio to receive either EES (n = 751) or bare-metal stents (n = 747). The primary endpoint was a patient-oriented composite endpoint of all-cause death, any myocardial infarction, or any revascularization. Secondary endpoints included a device-oriented composite endpoint of cardiac death, target vessel myocardial infarction, or target lesion revascularization; the individual components of the combined endpoints; and stent thrombosis. RESULTS: Complete 10-year clinical follow-up was obtained in 94.5% of the EES group and 95.9% of the bare-metal stent group. Rates of the patient-oriented composite endpoint and device-oriented composite endpoint were significantly reduced in the EES group (32.4% vs. 38.0% [hazard ratio: 0.81; 95% confidence interval: 0.68 to 0.96; p = 0.013] and 13.6% vs. 18.4% [hazard ratio: 0.72; 95% confidence interval: 0.55 to 0.93; p = 0.012], respectively), driven mainly by target lesion revascularization (5.7% vs. 8.8%; p = 0.018). The rate of definite stent thrombosis was similar in both groups (2.2% vs. 2.5%; p = 0.590). No differences were found between the groups in terms of target lesion revascularization (1.4% vs. 1.3%; p = 0.963) and definite or probable stent thrombosis (0.6% vs. 0.4%; p = 0.703) between 5 and 10 years. CONCLUSIONS: At 10-year follow-up, EES demonstrated confirmed superiority in combined patient- and device-oriented composite endpoints compared with bare-metal stents in patients with STEMI requiring primary percutaneous coronary intervention. Between 5- and 10-year follow-up, a low incidence of adverse cardiovascular events related to device failure was found in both groups. (10-Years Follow-Up of the EXAMINATION Trial; NCT04462315).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Brugaletta S, Gomez-Lara J, Ortega-Paz L, et al. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021. PMID: 33663733. doi:10.1016/j.jacc.2020.12.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。